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Abstract
Background: Intra-amniotic infection and/or inflammation (IAI) are important causes of preterm birth and early-onset
neonatal sepsis (EONS). A prompt and accurate diagnosis of EONS is critical for improved neonatal outcomes. We sought to
explore the cord blood proteome and identify biomarkers and functional protein networks characterizing EONS in preterm
newborns.
Methodology/Principal Findings: We studied a prospective cohort of 180 premature newborns delivered May 2004-
September 2009. A proteomics discovery phase employing two-dimensional differential gel electrophoresis (2D-DIGE) and
mass spectrometry identified 19 differentially-expressed proteins in cord blood of newborns with culture-confirmed EONS
(n=3) versus GA-matched controls (n=3). Ontological classifications of the proteins included transfer/carrier, immunity/
defense, protease/extracellular matrix. The 1
st-level external validation conducted in the remaining 174 samples confirmed
elevated haptoglobin and haptoglobin-related protein immunoreactivity (Hp&HpRP) in newborns with EONS (presumed
and culture-confirmed) independent of GA at birth and birthweight (P,0.001). Western blot concurred in determining that
EONS babies had conspicuous Hp&HpRP bands in cord blood (‘‘switch-on pattern’’) as opposed to non-EONS newborns
who had near-absent ‘‘switch-off pattern’’ (P,0.001). Fetal Hp phenotype independently impacted Hp&HpRP. A Bayesian
latent-class analysis (LCA) was further used for unbiased classification of all 180 cases based on probability of ‘‘antenatal IAI
exposure’’ as latent variable. This was then subjected to 2
nd-level validation against indicators of adverse short-term
neonatal outcome. The optimal LCA algorithm combined Hp&HpRP switch pattern (most input), interleukin-6 and neonatal
hematological indices yielding two non-overlapping newborn clusters with low (#20%) versus high ($70%) probability of
IAI exposure. This approach reclassified ,30% of clinical EONS diagnoses lowering the number needed to harm and
increasing the odds ratios for several adverse outcomes including intra-ventricular hemorrhage.
Conclusions/Significance: Antenatal exposure to IAI results in precocious switch-on of Hp&HpRP expression. As EONS
biomarker, cord blood Hp&HpRP has potential to improve the selection of newborns for prompt and targeted treatment at
birth.
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Introduction
Technological advances in newborn intensive care units have
increased survival of preterm infants, and thus awareness of the
need to improve outcomes [1]. Infection-related preterm birth
(PTB) presents a unique clinical circumstance given the need to
balance prolonging gestation against the risk of early-onset
neonatal sepsis (EONS) and consequently of poor neonatal
outcomes including respiratory distress syndrome (RDS), necro-
tizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD),
retinopathy of prematurity (ROP), intraventricular hemorrhage
(IVH) and death, independent of gestational age (GA) at delivery
[2–4].
Improving neonatal outcomes of premature infants has been
hampered by poor prediction and identification of EONS during
the antenatal and immediate postpartum periods [5]. With the
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of the aforementioned neonatal complications manifest days (e.g.
IVH) or even weeks post-delivery [6]. This suggests that the
decision to treat EONS and administer preventive strategies is
often taken late in the pathophysiologic process responsible for
sepsis-related end-organ damage [6,7].
Discovery of relevant biomarkers for better understanding of
EONS and for improved identification of affected newborns is
hypothetically possible through application of proteomics [2,7–
10]. The challenge, however, is to isolate the relevant biomarkers
amongst the huge number of identified proteins [11]. To discover
biomarkers characteristic of intra-amniotic infection and/or
inflammation (IAI), our group devised a stepwise strategy based
on sequentially applied mathematical filters [12]. We used surface-
enhanced laser desorption ionization time-of-flight mass spec-
trometry and named our analysis method Mass Restricted (MR)
scoring. Presence in amniotic fluid (AF) of at least 2 of the 4
discriminative biomarkers (defensin-2, defensin-1, S100A12,
S100A8) was validated as diagnostic of IAI [12]. We further
determined that presence of the S100A8 biomarker in AF of
women with IAI was associated with EONS [2,13]. Although the
MR score enables antenatal identification of fetuses at risk for
EONS, it has inherent limitations. AF is not easily obtainable nor
does it provide direct insight upon functional protein networks
relevant for EONS. Proteomics analysis of the cord blood (CB)
offers the potential to close these gaps. The objective of this study
was to perform a comprehensive analysis of the human CB
proteome to discover biomarkers that broaden our pathophysio-
logic understanding of EONS and improve identification of
affected newborns. Following our discovery phase, potential
proteomic targets were validated in an independent cohort of
premature neonates. Bayesian latent-class analysis (LCA) was
further employed to construct an unbiased model to calculate the
probability of ‘‘antenatal IAI exposure’’, which was then validated
against indicators of adverse short-term neonatal outcomes.
Methods
Ethics Statement
The Yale University Human Investigational Committee ap-
proved the study protocol. All mothers provided written informed
consent.
Study population and biological samples
Umbilical CB serum was retrieved from 180 consecutive
preterm singleton newborns born to mothers who had an
amniocentesis to rule out IAI (May 2004 to September 2009).
All fetuses were live-born and admitted to the Newborn Special
Care Unit (NBSCU) of Yale New Haven Hospital. In addition,
paired maternal and CB samples were obtained from 19 healthy
non-laboring women (GA: 38–40 weeks) undergoing elective
cesarean delivery at term. A flowchart of newborns and samples
analyzed during the discovery and validation phases is presented
in Figure 1.
Preterm newborns were delivered by women presenting with
symptoms of preterm labor, preterm premature rupture of
membranes (PPROM), and/or advanced cervical dilatation
($3 cm) [14]. Determination of GA was based on last menstrual
Figure 1. Flowchart representation of the stepwise study design and of the subject groups analyzed in each phase. Abbreviations:
PTL, preterm labor; PTB, preterm birth; PPROM, preterm premature rupture of membranes; NBSCU, New Born Special Care Unit; CB, cord blood; EONS,
early-onset neonatal sepsis; HCA, histological chorioamnionitis; IVH, intraventricular hemorrhage; ROP, retinopathy of prematurity; NEC, necrotizing
enterocolitis, BPD, bronchopulmonary dysplasia; 2D-DIGE, two-dimensional differential-gel-electrophoresis.
doi:10.1371/journal.pone.0026111.g001
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criteria: preterm singleton fetus born alive whose mothers had an
amniocentesis to rule out intra-amniotic infection and inflamma-
tion (IAI), admission to Yale NBSCU, appropriate growth for GA,
normal anatomic ultrasonographic survey. Exclusion criteria for
maternal enrollment included: chronic medical conditions (i.e.
hypertension, diabetes, thyroid disease), HIV, hepatitis or other
viral infections, fetal structural abnormalities or fetal heart rate
abnormalities requiring immediate intervention (i.e. bradycardia,
or prolonged variable decelerations). Inclusion criteria for the term
group: uncomplicated term pregnancy with indication for
cesarean delivery for breech or prior uterine scar, appropriately
grown fetus, reassuring fetal heart rate prior to surgery. Uterine
contractions and/or cervical change consistent with labor were
additional exclusion criteria for the term group.
Following amniocentesis each patient was followed prospective-
ly to delivery, independent of our research protocol. In the absence
of signs or symptoms of clinical chorioamnionitis (fever .37.8uC,
uterine tenderness and/or fetal tachycardia), AF laboratory results
suggestive of infection, non-reassuring fetal heart and/or abrup-
tion, PPROM was managed expectantly. Prior to delivery,
corticosteroids for lung maturity and antibiotics were administered
when clinically indicated [14]. Induction of labor or a surgical
delivery was performed for indications such as AF laboratory
results traditionally considered to indicate IAI, [2] prolapsed
umbilical cord and/or GA $34 weeks [16]. The neonatology
resuscitation team was present at the time of delivery for all
newborns.
For clinical management, diagnosis of IAI was established based
on well-recognized clinical, biochemical and microbiological AF
tests which included: glucose concentration (cut-off of #15 mg/
dL), lactate dehydrogenase activity (LDH, cut-off $419 U/L),
white blood cell count (WBC, cut-off $50 cells/mm3), Gram stain
and microbiological cultures for aerobes, anaerobes, Ureaplasma
and Mycoplasma species [17,18].
In all 180 cases, hematoxylin & eosin-stained sections of
extraplacental membranes (amnion and chorio-decidua), chorion-
ic plate and umbilical cord were examined systematically for
inflammation. Three histological stages of chorioamnionitis [19]
(stage I: intervillositis, stage II: chorionic inflammation, and stage
III: full-thickness inflammation of both chorion and amnion) were
complemented by a previously described histological grading
system that includes 4 grades of inflammation of the amnion,
chorio-decidua and umbilical cord [20].
Cord blood was retrieved by sterile puncture of the umbilical
vein after delivery. Samples were centrifuged for 10 min (1,000g,
4uC) and the serum aliquoted and stored at 280uC.
Diagnoses of EONS and of other short-term neonatal
outcomes
Neonatal hematological indices were assessed from blood
specimens obtained within 2-hours post-delivery. The diagnosis
of EONS was ‘‘presumed’’ in the presence of at least two of the
following hematological criteria: absolute neutrophil count of
,7,500 or .14,500 cells/mm3; absolute band count .1,500
cells/mm3; immature/total neutrophil (I:T) ratio .0.16; platelet
count ,150,000 cells/mm as previously described [13]. EONS
was termed ‘‘confirmed’’ when neonatal blood cultures returned a
positive result. ‘‘Clinical EONS’’ was defined as the presence of
‘‘presumed’’ EONS corroborated with clinical symptoms and/or
‘‘confirmed’’ EONS at #72 hours after birth. All newborns with
clinical EONS received intravenous antibiotics in NBSCU.
Evaluation for intra-ventricular hemorrhage (IVH) was done
per institutional protocol using serial cranial ultrasounds on days 3,
7–10 and 30 of life [6,21]. Additional scans were performed if
clinically indicated. The diagnosis and grading of IVH was
established by experienced pediatric radiologists: grade 1,
germinal matrix hemorrhage; grade 2, intraventricular blood
without distension of the ventricular system; grade 3, blood filling
and distending the ventricular system and grade 4, parenchymal
involvement of hemorrhage, also known as periventricular venous
infarction [21]. The ophthalmologist classified retinopathy of
prematurity (ROP) in each eye according to the international
classification [22]. Clinical, metabolic, hematologic and abdom-
inal x-ray abnormalities (i.e pneumatosis intestinalis, portal venous
gas) criteria were used to diagnose necrotizing enterocolitis (NEC)
[23]. Bronhopulmonary dysplasia (BPD) was defined as need of
receiving supplemental oxygen at 36 weeks’ corrected postmenstr-
ual age [24]. End of newborn follow-up was March 2010.
Proteomics discovery phase
Characteristics of cases used for discovery. To identify
biomarkers and functional protein networks characteristic of
EONS, we first employed two-dimensional differential gel
electrophoresis (2D-DIGE) on select CB samples. Three preterm
newborns (GA: median, interquartile range [IQR]: 28 [25–30]
weeks) had confirmed EONS by positive blood cultures for
Escherichia coli. All had elevated fetal inflammatory status by CB
interleukin-6 (IL-6) and their placentas had histological
chorioamnionitis [25]. Three neonates without confirmed or
presumed EONS, born at similar GA (26 [25–30] weeks) in the
setting of idiopathic PTB (absent IAI, negative AF cultures, absent
histological chorioamnionitis) were used as controls. There was no
statistical GA difference between EONS and idiopathic PTB cases
(paired t-test, P=0.169).
2D-DIGE protocol. Identification of low abundant proteins
was facilitated with the aid of albumin and IgG removal kit (GE
Healthcare, Piscataway, NJ), as previously described [26]. Cord
blood proteins (50 mg) were labeled with either Cy5 (confirmed
EONS group) or Cy3 (idiopathic PTB group). A reference pool
(25 mg total protein) was labeled with Cy2 and used as internal
control. For each pair, labeled samples were pooled and isoelectric
focusing was performed on the Ettan-DIGE system (GE
Healthcare, Piscataway, NJ) using an isoelectric point range of
3–10 followed by SDS-PAGE on a 12% gel for the second
dimension. After spot detection, automatic background correction,
spot volume normalization and volume ratio calculation, dye
ratios were determined using DeCyder Extended Data Analysis
software (GE Healthcare).
Protein identification and data mining. Spots
corresponding to $1.5-fold changes were robotically excised
using the Ettan Spot Picker instrument (GE Healthcare) and
subjected to automated in-gel tryptic digestion on the Ettan TA
Digester (GE Healthcare). Automated MALDI-MS/MS spectra
were acquired on the 4800 TOF/TOF proteomics analyzer
(Applied Biosystems, Foster City, CA). The resulting peptide
sequences along with spot information (Cy5/Cy3 ratio, location
on gels) were uploaded in the web-accessible Yale Protein
Expression Database (YPED http://medicine.yale.edu/keck/
proteomics/yped/index.aspx) [27]. A combined peptide mass
fingerprint and tandem mass spectrometry search was done.
Protein sequences were analyzed with Applied Biosystems GPS
Explorer software and Mascot algorithm against the non-
redundant National Center for Biotechnology Information
(NCBInr) and the International Protein Index (IPI) databases
[28]. A comprehensive list of probable identities (Mascot scores of
$81 for NCBInr and $61 for IPI) was generated. Unique IPI
identities differentially expressed $1.5 fold were classified using
Cord Blood Biomarkers and Neonatal Sepsis
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(http://www.pantherdb.org). Identities were grouped into families
and subfamilies of shared functions, and ontologically categorized
by biological process, molecular function and pathway. A
reductionist algorithm was applied to extract identities
differentially expressed in at least two of the three 2D-DIGE
gels. This approach pointed toward haptoglobin (Hp),
haptoglobin-related protein (HpRP), a-fetoprotein (AFP),
vitamin-D binding-protein (VDBP), apolipoprotein A4 (APOA4),
apolipoprotein E (APOE) and apolipoprotein H (APOH) as
potential CB biomarkers for EONS.
1
st-Level validation phase
Immunoassays. The HpRP gene product has .90%
sequence homology with Hp [29]. Identification of a distinct
mRNA coding for HpRP continues to be elusive [30].
Furthermore, a specific antibody that discriminates HpRP from
Hp does not exist. Thus, for the purpose of this study we refer to
Hp&HpRP as the combined Hp and HpRP immunoreactivity
measured with anti-Hp antibodies. Samples were diluted with
blocking buffer (5% non-fat dry milk) 100, 1,000 or 10,000-fold
(CB) or only 10,000-fold (maternal blood). A mixed phenotype Hp
standard (Hp1-2, Sigma) was used to prepare a 7-point standard
curve (250-3.9 ng/ml). Immunoassays for AFP (R&D Systems,
Minneapolis, MN), VDBP (ICL Inc, Newberg, OR), actin-free
VDBP (Alpco, Salem, NH), APOA4 (Cederlane Labs, Burlington,
NC), APOE (MBL International, Woburn, MA and APOH
(Enzyme Research Laboratories, South Bend, IN) were performed
according to each procedure summary. In pilot experiments we
determined the CB serum optimal sample dilutions for AFP
(50,000-fold), VDBP (total 50,000-fold, actin-free 5,000-fold),
APOA4 (100-fold), APOE (500-fold) and APOH (10,000-fold).
IL-6 (Pierce-Endogen, Rockford, IL) was measured in AF and CB
to assess the inflammatory status of the two biological
compartments. All samples were tested in duplicate by
investigators unaware of case origin or outcome. Cord serum
total protein was quantified using bicinchoninic acid (BCA) assay
(Pierce Biotechnology, Rockford, IL).
Hp&HpRP Western blotting. Haptoglobin is a tetrameric
protein with two a and two b-chains linked by disulfide bonds. In
humans, Hp occurs in two co-dominant allelic forms, Hp1 and
Hp2, which differ in the length of the a-chain [31]. The human
population has 3 major Hp phenotypes (Hp1-1, Hp2-2 and the
heterozygous Hp1-2), derived from variations in the a-chain with
identical b-chains [29]. Absence of Hp at protein level denotes
Hp0-0 phenotype (ahaptoglobinemia). Differences in Hp
phenotypes can be distinguished by Western blotting.
SDS-PAGE gels (10-20%, InVitrogen, Carlsbad, CA) were
loaded with equal amounts of CB protein (2 mg/lane) mixed 1:2
with reducing sample buffer (Bio-Rad, La Jolla, CA) and boiled for
5 min. After electrophoretic transfer, nitrocellulose membranes
(Bio-Rad) were blocked with 5% milk and then incubated
overnight at 4uC rabbit anti-Hp polyclonal antibody (1:3,000,
Sigma, St Louis, MO). Detection was performed using biotinylated
goat anti-rabbit secondary antibody (1:5,000, Jackson Immunor-
esearch, West Grove, PA) followed by streptavidin-linked
horseradish peroxidase, (1:8,000, Amersham Biosystems, Piscat-
away, NJ), chemiluminescence (ECL-Plus, Amersham) and a
timed 3 min. exposure to film (Kodak Biomax). Optical density of
the bands of interest was analyzed with Image J software (NIH,
http:\\ rsb.info.nih.gov). The results were expressed as the optical
density of each band and as total optical density calculated from
the sum of a- and b-chains. Purified Hp from blood of adults with
known phenotypes (Hp1-1, Hp1-2 and Hp2-2, Sigma, St. Louis,
MO) was used as positive control.
In the current study, a detectable Hp b-chain (,42 kDa) on
Western blot was indicative of a ‘‘switch-on’’ in Hp expression. Hp
phenotypes were defined by additional presence of a-chain bands
at either ,9 kDa (a
1: Hp1-1), ,20 kDa (a
2: Hp2-2) or both (Hp1-
2). In select samples (n=20) Hp phenotypes were determined both
by the above western blot procedure and the classical peroxidase
method [32]. We noted that our denaturing and reducing Western
blot protocol was far more sensitive for detecting expressed
Hp&HpRP patterns in CB compared to the peroxidase method
which in our hands appeared suitable only for adult blood (data
not shown).
2
nd-Level validation phase
We applied latent-class analysis (LCA), a statistical solution that
has gained increased acceptance when a perfect gold standard
diagnostic test does not exist [33]. Briefly, LCA assumes that a
hidden (latent) variable is responsible for heterogeneity among
observed variables. By studying the patterns of co-variation among
observed variables, the nature of the latent variable can be
characterized. Specifically, rather than testing an a priori classifier
(i.e. biomarker level above or lower than a pre-determined cut-off),
the fit of a series of different models is examined. Each model
combines several indicators (variables involved in cluster forma-
tion) and covariates (other demographical or clinical variables),
potentially adding to cluster characterization. A cluster model is
examined first, and then clusters are added until no further
improvement in classification is observed. For the purpose of this
study the latent variable was set as ‘‘antenatal IAI exposure’’. This
variable was then investigated for its ability to predict short-term
adverse neonatal outcomes in comparison with the clinical
diagnosis of EONS which represents the current standard of care.
Since sepsis is a known ascendant of IVH, the 2
nd-level validation
phase was powered to detect differences in frequency of IVH with
respect to clinical EONS.
Statistical analyses
Normality testing was performed using the Shapiro-Wilk test.
Data were compared with one-way ANOVA followed by Holm-
Sidak method (parametric) or Kruskal-Wallis on ranks followed by
Dunn’s tests (non-parametric) as appropriate. Pearson correlations
were used to measure co-linearity between the selected indepen-
dent variables as well as other relevant relationships between
dependent and independent variables. Comparisons between
proportions were done with Chi-square tests. The phi-coefficient
of correlation (W), an index of agreement for binary data was
calculated. Stepwise multivariable regression analysis was used to
determine concurrent relationships between variables and to
correct for possible influences of GA and birthweight. Statistical
analyses were performed with SigmaPlot 11.0 (Systat Software),
MedCalc (Broekstraat, Belgium) and Latent Gold 4.5. (Statistical
Innovations) softwares. A P ,0.05 was considered statistically
significant.
Goodness of fit of LCA models was evaluated using the
Bayesian Information Criterion (BIC) and Akaike information
criterion (AIC) [33]. Lower BICs indicate model improvement.
Conditional bootstrap re-sampling procedures (500 random
iterations) were employed to compare fit indices between models.
The input of each indicator to the final model was measured by
the nominal correlation coefficient Goodman-Kruskal tau-b (GK-
h). Finally, a posterior probability classifying each case to each
cluster of the final model was calculated. Odds ratios (OR),
positive likelihood ratio (+LR, number of times more likely that a
Cord Blood Biomarkers and Neonatal Sepsis
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outcome compared to newborn with a negative diagnosis),
negative likelihood ratio (-LR, number of times more likely that
a newborn with a negative diagnosis will not develop the adverse
outcome compared to newborn with a positive diagnosis) and
number needed to harm (NNH, number of subjects needed to be
exposed to a risk factor to cause harm in one subject that otherwise
would not have been harmed) were computed to determine the
risk of adverse neonatal outcomes. The lower the NNH the worse
the risk factor.
Results
Differences in CB serum proteome of newborns with
confirmed EONS
Mapping of CB proteomes identified 414 distinct protein spots
on the three 2D-DIGE gels as shown in Figure 2. Cy5 (EONS)/
Cy3 (idiopathic PTB) ratio was $1.5-fold different in 69 spots
which were all subjected to identification by mass spectrometry.
Sixty-seven spots matched at least one GenBank sequence
identifier (down-regulated: 17 spots, up-regulated: 50 spots). With
1-5 identifiers/spot and multiple spots matching to the same
identifier, our most inclusive list had 135 unique NCBInr
identities. The analogous analysis against IPI human database
found 70 unique IPI identities in at least 1/3 gels. Next, we
excluded identifiers originating from a single 2D-DIGE gel with
the rationale that these were most likely to result from randomness
(technical or biological). This approach left us with 19 unambig-
uous, unique IPI human identities that changed in the context of
EONS $1.5-fold in at least 2/3 gels. PANTHER further
converged the 19 differentially expressed identities by matching
several IPI identities to the same protein precursor as shown in
Table S1.
Data mining using PANTHER distributed the 19 IPI identities
into 5 distinct molecular functions and 9 biological processes with
transport, immunity/defense and protease/extracellular matrix at
the top of the list (Figure 3). Pending validation, this led us to
conclude that CB of EONS newborns is potentially characterized
by net up-regulation in HpRP (60-fold), Hp (33-fold), alpha-
fetoprotein (7-fold), VDBP (2-fold) and by net down-regulation of
albumin (6-fold), apolipoproteins APOA4 (5-fold), APOE (3-fold)
and APOH (3-fold). Spots matching to a2-macroglobulin changed
in divergent directions resulting in null net change.
Results of 1
st-level validation
Characteristics of cases used for 1
st-level
validation. The clinical characteristics of the mothers and
newborns that provided the CB samples used in the 1
st-level
validation (n=174) are included in Table S2. Results of clinical
laboratory analyses are included in Table S3. Mothers of neonates
with EONS were of lower GA at enrollment (amniocentesis), had
shorter amniocentesis-to-delivery intervals and delivered at earlier
GAs newborns with lower birthweights and lower Apgar scores.
GA at delivery is an important determinant of neonatal maturity
and outcome. Following correction for GA at birth we determined
that EONS impacted independently on the 1-minute Apgar score.
Women who delivered neonates with EONS more often had AF
biochemical and microbiological tests results consistent with IAI.
There was a higher frequency of histological chorioamnionitis and
funisitis in the EONS group. Neonatal hematological tests and
indices that were affected by EONS independent of GA were:
neonatal WBC, neutrophil and lymphocyte counts, ABC and I:T
ratio.
Upon admission to NBSCU, 41 newborns were diagnosed with
‘‘presumed’’ EONS and placed promptly on i.v. antibiotics. In
only 3 of these blood cultures returned a positive result. Blood
cultures tested positive in another 4 newborns that did not show
evidence of ‘‘presumed’’ EONS at admission. Thus, a total of 45
newborns from the 1
st-level validation cohort had clinical
diagnoses of EONS (excluding the 3 newborns used in the
discovery phase). Together, these results point to the relevance of
this cohort for external validation of potential CB biomarkers
Figure 2. Merged 2D-DIGE images of the 3 gels used during the proteomics discovery phase and representative spots identified by
mass spectrometry. Spots upregulated at least 1.5-fold are outlined in blue and spots down-regulated at least 1.5-fold are outlined with red. The
squared regions are shown magnified below each gel (A, B or C) with matched unambiguous protein identities and direction of change represented
by arrows. Apo, apolipoprotein; Hp, haptoglobin; HpRP, haptoglobin-related protein.
doi:10.1371/journal.pone.0026111.g002
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intra-amniotic infection, inflammation and EONS.
Immunoassay results. We chose to validate those
proteomic targets with a net change $3-fold (HpRP, Hp, AFP,
VDBP, APOA4, APOE and APOH). Despite albumin depletion
prior to 2D-DIGE, we noted consistent changes in 12 spots
matching to albumin (45-72kDa, Table S1). Although albumin
variants and fragments thereof could be true biomarkers, specific
knowledge on antibody affinity against each of the peptides is
lacking at this time. Thus, changes in serum albumin were
indirectly validated through the non-immunological measure of
total protein concentration.
The results of validation immunoassays and of the additional
relevant CB analytes (total protein and IL-6) are presented in
Table 1. Cord serum Hp&HpRP immunoreactivity, but not that of
the other proteomic targets, was significantly elevated in newborns
with clinical EONS. Neonates with EONS had lower total CB
protein and higher IL-6 levels. Following correctionfor GA at birth,
only Hp&HpRP and IL-6 remained independently impacted by
clinical EONS (GA-corrected levels P=0.001 for both).
Western blotting of CB Hp&HpRP. Figure 4A shows
representative Western blots of CB serum of newborns with (lanes
1–3) and without (lane 4) clinical EONS. We found that a
significantly higher number of EONS newborns displayed the Hp
switched-on pattern at birth (Yes EONS: 78% (35/45) vs. No
EONS36%(46/129),P,0.001).A Hpswitched-offpattern(Hp0-0)
was characterized by significantly lower ELISA immunoreactivity
compared to all other phenotypes (P,0.001, Figure 4B). Among
newborns with switch-on pattern, the Hp phenotype impacted on
ELISAimmunoreactivitywith Hp1-1measuringlowercomparedto
both Hp1-2 (P,0.001) and Hp2-2 (P=0.002) (Figure 4B),
independent of neonatal race, gender and GA at birth (P=0.011).
To provide further evidence that precocious switch-on of
Hp&HpRP is EONS-specific, we performed Western blotting and
ELISA on matched CB and maternal blood from healthy
gestations. Representative Western blot of 3 term maternal-fetal
dyads are shown Figure 4C. No term baby (0/19) had switched-on
Figure 3. Pathway analysis results of the cord blood proteome dys-regulated in cord blood of premature newborns with culture
confirmed EONS. Identities differentially expressed at least 1.5-fold were distributed by molecular function (A) and biological process (B) using
PANTHER system.
doi:10.1371/journal.pone.0026111.g003
Table 1. Results of cord blood analytes measured in the 1
st-
level validation (n=174).
Variable NO EONS (n=129) YES EONS (n=45) P value
Potential cord blood proteomic biomarkers
Hp&HpRP, ng/mL { 666 [17-6,818] 9,013 [4,449-12,463] ,0.001*
AFP, mg/mL 355 [213-606] 320 [154-466] 0.258
VDBP, total, mg/mL 381 [270-477] 438 [335-523] 0.145
VDBP, actin bound,
mg/mL
205 [126-275] 232 [152-366] 0.132
VDBP, actin free,
mg/mL
144 [112-193] 161 [118-203] 0.549
APOA4, ng/mL 2,373 [1,850-2,836] 2,143 [1,837-2,577] 0.338
APOE, mg/mL 284 [215-397] 331 [204-484] 0.404
APOH, mg/mL 137 [121-166] 145 [94-177] 0.950
Other research analytes
Total protein, mg/mL 42 [37-49] 35.9 [31.6-43.6] 0.008
IL-6, pg/mL 8 [6-37] 106.5 [22.3-506.9] ,0.001*
{Data presented as median [interquartile range] and analyzed by Mann Whitney
tests.
*Postnatal variables remaining significant for EONS after correction for GA at
birth in multivariate analysis.
Abbreviations: EONS, early-onset neonatal sepsis; Hp&HpRP, combined
haptoglobin and haptoglobin-related protein immunoreactivity; AFP, a-
fetoprotein; VDBP, vitamin-D binding-protein; APOA4, apolipoprotein-A4; APOE,
apolipoprotein-E; APOH, apolipoprotein-H; IL-6, interleukin-6.
doi:10.1371/journal.pone.0026111.t001
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had detectable Hp chains (19/19), as expected for normal adult
subjects. ELISA showed marked difference in Hp&HpRP between
maternal and term cord serum with maternal exceeding CB
concentrations by .3 orders of magnitude (P,0.001, Figure 4D).
Preterm newborns with Hp switched-off pattern had similar
Hp&HpRP to healthy term newborns (P=0.189). Preterm
newborns with switched-on pattern had significantly higher
Hp&HpRP (P,0.001) compared to healthy and to preterm
switched-off babies, albeit lower than maternal samples (P,0.001).
Considerations regarding determination of CB
Hp&HpRP by ELISA and by Western blot. In Figure 5A
we illustrate differences in optical density (OD) readings obtained
with standard curves prepared with Hp purified from adult blood
of different phenotypes: Hp1-1, 1-2 and 2-2. The same
concentration of Hp1-1 measured less in ELISA compared to
Figure 4. Cord blood haptoglobin (Hp) and haptoglobin-related protein (HpRp) immuno-reactivity revealed by Western blot (A&C)
and ELISA (B&D) using antibodies reactive with both Hp and HpRP. (A) Western blot of umbilical vein (UV) serum from 4 preterm newborns
of similar gestational age at birth. The newborns in Lanes 1-3 were categorized as having early-onset sepsis (EONS) based on clinical manifestations
and hematological indices and all received i.v. antibiotics. The newborn in Lane 4 had a negative sepsis work-up. Blood cultures remained negative for
all 4 newborns. The presence of a conspicuous immunoreactive band corresponding to the b-chain (,42 kDa) in Lanes 1-3 is consistent with our
defined switched-on Hp pattern. The absence of this band indicates for a switched-off pattern in Lane 4. The band ,9 kDa (Lanes 1&2) corresponds to
the a1-chain whereas the band at ,20 kDa (Lanes 2-3) corresponds to the a2-chain. Thus, the cord blood Hp patterns and phenotypes depicted in
this gel are: switched-on pattern and Hp1-1 (Lane 1), switched-on pattern and Hp1-2 (Lane 2), switched-on pattern and Hp2-2 (Lane 3) and switched-
off pattern and Hp0-0 (Lane 4). In our cohort, among preterm newborns with switched-on Hp pattern (present b-chain, n=81), the distribution of Hp
phenotypes was as follows: 6.0% Hp0-0 (5/81, no a-chain detected), 19.3% (16/81) Hp1-1, 32.5% (26/81) Hp1-2, and 42.1% (34/81) Hp2-2. The higher
band intensity of the a2-chain compared to that of the a1-chain suggest that phenotype impacts on total Hp immunoreactivity. (B) Impact of Hp
phenotypes on Hp&HpRP immunoreactivity as measured by ELISA. The red line indicates the group’s median. Groups assigned different letters are
statistically different at a P,0.05 (Kruskal-Wallis ANOVA). (C) Western blot of 3 representative maternal (Mat) and UV serum retrieved from women
with normal deliveries at term. Note the switched-off pattern of the cord blood in contrast to the switched-on pattern of the adult blood. The Hp
phenotypes of the mothers are Hp2-2 (Cases #1 and #2) and Hp1-2 in Case #3. (D) Quantitative comparison of Hp&HpRP immunoreactivity
measured by ELISA in 19 UV and maternal blood (MB) serum from 19 normal deliveries at term relative to Hp&HpRP immunoreactivity measured in
preterm UV with either switched-off or switched-on Hp pattern. The red line indicates the group’s median. Groups assigned different letters are
statistically different at a P,0.05 (Kruskal-Wallis ANOVA).
doi:10.1371/journal.pone.0026111.g004
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suggests that different Hp phenotypes impact on Hp&HpRP
ELISA levels and argues that reliance on ELISA level alone
remains simplistic when assessing Hp&HpRP as CB biomarker.
There was a significant direct correlation between the total
optical density of Hp&HpRP immunoreactivity by Western blot
and by ELISA (R=0.863, P,0.001, Figure 5B). A Hp&HpRP
immunoreactivity .3,370 ng/mL in ELISA was best in indicating
a switched-on Hp pattern in our preterm newborns (ROC area:
0.998, 95%CI [93.5–100], Figure 5C). This indicates that a binary
indicator derived from ELISA immunoreactivity can potentially
be used in lieu of Western blotting for determination of the Hp
switch pattern. However, until isoform-specific antibodies are
available, Western blotting may be an accessible method for
concurrent determination of the Hp phenotype.
Results of 2
nd-level validation
Latent-class analysis (LCA) to identify the probability of
antenatal IAI exposure. This analysis included all newborns in
the study (n=180). Preterm neonates who displayed the Hp
switched-on pattern had significantly elevated CB IL-6 levels
independent of EONS status (P,0.001, Figure 6). In multivariate
analysis, CB IL-6 was independently impacted by the Hp switch-
on pattern (P,0.001), number of expressed Hp2 alleles (none for
Hp0-0 or Hp1-1, one for Hp1-2 and two for Hp2-2 phenotype;
P=0.005), and a clinical diagnosis of EONS (P=0.003). Thus,
chosen LCA discriminatory variables (indicators) were Hp switch
pattern, IL-6 level and presumed EONS, as culture results are
unavailable shortly after birth. Covariates were neonatal race,
gender, Hp phenotype, GA and membrane status. In Table 2 we
display the goodness of fit results for our 4 models. A decrease in
the values of the Bayesian Information Criterion (BIC) indicates an
improvement in the fit, with increasing the number of clusters.
Generally speaking, models with P.0.05 provide an adequate fit
(no significant difference between the model and the data). The
model with the fewest number of parameters (most parsimonious)
should be selected. Based on these criteria, Model 2 (2-cluster
solution) appeared the best fit of our data. We next compared
Model 2 with Model 3 using bootstrap statistical procedures. This
analysis indicated that the improvement in classification rendered
by Model 3 did not reach statistical significance (-2LL difference:
23, P=0.07). Thus, Model 2 (the 2-cluster solution) was chosen as
the best fit for our newborn population.
In our LCA model all 3 indicators contributed significantly
(P,0.001), albeit unequally to data clustering (Table 3). Most of
the input was achieved from Hp switching (GK-h: 0.98). The least
input was obtained from presumed EONS (GK-h: 0.14). These
results are graphically represented in Figure 7 which illustrates the
non-overlapping characteristics of the two clusters. Cluster-1 was
characterized by very low probability for Hp switch-on pattern
and low probabilities for presumed EONS and elevated CB IL-6
(.100 pg/mL). Cluster-2 was characterized by a high probability
Figure 5. Considerations for determination of cord blood Hp&HpRP immunoreactivity. (A)Demonstration that Hp phenotype impacts on
optical density (OD) measured in ELISA. Samples of adult Hp purified from individuals with known phenotype (Hp1-1, 1-2 or 2-2, purchased from
Sigma) were diluted progressively in the range of the standard curve and analyzed in ELISA (n=3 independent observations); (B) Relationship
between cord blood Hp&HpRP immunoreactivity measured by ELISA and by Western blot in denatured and reducing conditions (n=180). The
continuous red line represents the linear regression line, the red dotted lines mark the 95% confidence interval and the dotted black lines the 95%
prediction interval; (C) ROC analysis which demonstrates the relationship between Hp switch-on pattern and Hp&HpRP cord blood levels measured
by ELISA. An ELISA cut-off of 3,370 ng/mL was deemed optimal to discriminate between the Hp switch-on and Hp switch-off pattern by Western blot
(n=180).
doi:10.1371/journal.pone.0026111.g005
Figure 6. Cord blood interleukin-6 levels of preterm newborns
in the study. Cases (n=180) were stratified by clinical diagnosis of
early-onset neonatal sepsis (EONS, Yes or No) and by haptoglobin (Hp)
switch pattern (ON or OFF). The red line indicates the group’s median.
Groups sharing at least one common letter are statistically not different
at a P.0.05 (Kruskal-Wallis ANOVA).
doi:10.1371/journal.pone.0026111.g006
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phenotype showed statistical disparity between the two clusters
(P=0.002).
Bayesian posterior probabilities of antenatal IAI exposure
derived from the analysis of our study population are shown in a
flowchart format in Figure 8. Each case was distributed to either
cluster-1 (‘‘likely non-exposed’’, n=92) or cluster-2 (‘‘likely ex-
posed’’, n=88) based on a posterior probability cut-off of 50%
(equivalent to equally probable categories and a useless algorithm).
Most of the input for the algorithm is derived from two CB
indicators (Hp switch pattern and IL-6 $100 ng/mL). For the
majority of cases (97%), the Hp switch pattern alone dictated the
cluster assignment. Yet, 5 cases presenting with Hp switch-off
pattern were solved by our model to cluster-2 driven by the CB IL-
6$100 pg/mL. Although presumed EONS had the lowest
discriminative power compared to the other LCA indicators and
did not change the cluster assigned by the combination of the
other two CB markers, it still contributed to the certainty level with
which each case was assigned to each cluster.
The agreement between our novel classification and clinical
EONS was ‘‘moderate’’ (W=0.416, P,0.001). The cluster
classification agreed with clinical diagnosis in only 69% (124/
180) of cases. Our new algorithm identified a high probability of
exposure in 27% (48/180) of cases deemed clinically EONS
negative. In the remaining 4% (8/180) of cases, although these
had been classified clinically as having EONS, our model argued
against an exposed state. This suggests that based on current
clinical practice, ,30% of newborns are potentially misdiagnosed
with respect to antenatal exposure to IAI. The results of cluster
classification based on the three indicators particularized to the
subgroup of newborns with positive blood cultures (n=10), are
presented in Table S4. Within this selected cohort, 20% (2/10) of
newborns were found to be ‘‘likely non-exposed’’. All the
newborns were clustered as ‘‘likely exposed’’ although only 50%
(4/8) had a diagnosis of presumed EONS with prompt initiation of
antibiotic treatment.
Relationships between antenatal IAI exposure and short-
term neonatal outcomes. Next we investigated the
relationships between our new cluster classification and adverse
neonatal outcomes and whether it could improve their prediction
as compared to the current diagnosis of EONS. Our analysis was
adequately powered to detect a relationship between clinical
EONS and IVH as single outcome (power=0.808, a=0.05) and
as part of the composite outcome IVH and death (power=0.861).
In multivariate logistic regression the two composite newborn
outcomes were significantly predicted by the combination of GA
(P,0.001), antenatal IAI exposure (cluster-2 probability .50%,
P,0.001) and the Hp phenotype (P,0.05). Excluded from the
model were: CB IL-6, Hp&HpRP immunoreactivity by ELISA,
presumed EONS and clinical diagnosis of EONS. As shown in
Figure 9 and presented in more detail in Table 4, we determined
that for all adverse outcomes with the exception of NEC, the ORs
and +LR increased in the context of the new model. Using this
algorithm, the +LR [95%CI] for the composite outcome ‘‘IVH or
death’’ was 7.1 [2.9–17.4] versus 2.9 [1.7–5.0] for clinical EONS
diagnosis. +LR for prediction of newborns developing ‘‘at least one
major adverse outcome’’ was 4.3 [2.4–7.7] for our algorithm
versus 2.8 [1.8–4.3] for clinical EONS. Negative LRs remained
largely unchanged (composite outcome ‘‘IVH or death’’, cluster-2
inclusion: 0.65 [0.55–0.77] versus clinical EONS: 0.68 [0.54–
0.87]; development of ‘‘at least one major adverse outcome’’,
cluster-2 inclusion: 0.55 [0.44–0.70] versus clinical EONS: 0.53
[0.38–0.74]). Additionally, the lower NNH resulting from our
Table 2. Fit indices for possible latent-class analysis (LCA) models.
Model # clusters LL BIC AIC Npar L
2 df P value Class Err
Model 1 1 -329.54 674.65 665.07 3 451.23 177 ,0.001 0.000
Model 2* 2 -177.84 428.38 383.68 14 147.84 166 0.84 0.002
Model 3 3 -166.34 462.50 382.68 25 124.84 155 0.97 0.032
Model 4 4 -157.27 501.49 386.55 36 106.70 144 0.99 0.039
*Based on these considerations, Model 2 (the 2-cluster solution) was chosen as the optimal fit to our newborn population.
Abbreviations: LL, log-likelihood; BIC, Bayesian Information Criterion; AIC, Akaike Information Criterion. These statistical indicators weigh out the fit and parsimony by
adjusting the LL to account for the number of parameters in the model. The lower the BIC and AIC values, the better the model. Npar, number of parameters; L2,
likelihood-ratio goodness-of-fit value for the current model. df, degrees of freedom; Class Err, classification error. When classification of cases is based on modal
assignment (to the class having the highest membership probability), the proportion of cases that are expected to be misclassified is reported by this statistical
indicator. The closer this value is to 0 (zero) the better.
doi:10.1371/journal.pone.0026111.t002
Table 3. Contribution of indicator variables in discriminating
between latent clusters and partitioning of covariates
between the clusters.
Variable Variable levels Wald * P value G-Kh **
Indicators
Hp&HpRP switch pattern 2 (ON or OFF) 14.88 ,0.001 0.98
Cord blood
IL-6 $100 pg/mL
2 (YES or No) 36.63 ,0.001 0.30
Presumed EONS 2 (YES or NO) 21.32 ,0.001 0.14
Covariates
Hp phenotype 4 (Hp0-0, 1-1, 1-2, 2-2) 14.57 0.002 NA
Gender 2 (male or female) 0.40 0.530 NA
Race 2 (Caucasian or not) 1.97 0.160 NA
GA at delivery 2 (,30 wks
or $30 wks)
1.00 0.320 NA
Membrane status 2 (PPROM or intact) 1.97 0.160 NA
*Wald statistic values are provided to assess the statistical significance of each
nominal parameter. A non-significant associated P value means that the
indicator does not discriminate between the clusters in a statistically significant
way.
**G-Kh (Goodman Kruskal tau b) is a more general coefficient of association
between two nominal variables. In this case it represents the strength of
association between the respective indicator and our latent variable ‘‘antenatal
IAI exposure’’. The closer to 1 the G-Kh value, the higher the association and the
contribution of the respective indicator in discriminating between latent
clusters of the final model.
doi:10.1371/journal.pone.0026111.t003
Cord Blood Biomarkers and Neonatal Sepsis
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26111Figure 7. Results of Latent Cluster Analysis (LCA) applied to the population of preterm newborns in the study. (A) Profile plot of the 2-
cluster model solution segregating the preterm newborn in this study (n=180) by probability of antenatal exposure to intra-amniotic infection and/
or inflammation (IAI). The x-axis lists the discriminative indicators and significant covariates with their modal characteristic (in red) for which the
probability level expected to manifest in each of the two latent clusters is displayed on the y-axis. Newborns in cluster-1 are characterized by low
probability of a switch-on haptoglobin (Hp) pattern, IL-6$100 pg/mL hematological indices consistent with presumed early-onset sepsis (EONS). In
contrast, newborns in cluster-2 are characterized by high probability of Hp switch-on pattern along with increased probabilities for cord blood IL-
6$100 pg/mL and for presumed EONS.
doi:10.1371/journal.pone.0026111.g007
Figure 8. Clustering flowchart based on probability of ‘‘antenatal IAI exposure’’. Posterior probabilities for inclusion in cluster-2 were
calculated for all 8 possible combinations of indicators (haptoglobin & haptoglobin [Hp&HpRP] switch pattern, cord blood IL-6, presumed EONS) and
their modal characteristics. The number of newborns presenting each combination is included in parentheses. All newborns with cluster-2 probability
levels .50% (black boxes) were considered ‘‘likely exposed’’. Alternatively, a diagnosis of ‘‘likely non-exposed’’ was assigned to newborns with
cluster-2 probability levels ,50% (grey boxes).
doi:10.1371/journal.pone.0026111.g008
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a much stronger risk factor of neonatal morbidity than a diagnosis
EONS in the context of current clinical practice.
Relationships of Hp phenotypes with neonatal
outcomes. Figure 10 demonstrates a disparity in adverse
neonatal outcomes based on probability of antenatal IAI
exposure and Hp phenotype. Among exposed newborns, those
with Hp switched-on to Hp2-2 phenotype had the lowest
incidence of IVH or death (Chi-square P,0.001) and of major
morbidities (P=0.043), despite no difference in GA at birth
(P=0.410).
Discussion
There are several reasons why it is difficult to accurately
diagnose EONS in current clinical practice. First, bloodstream
infection in EONS fluctuates widely from 8% to 73% [34]. Many
newborns with ‘‘presumed EONS’’ have nonspecific clinical
manifestations (i.e lethargy, apnea, respiratory distress, hypoper-
fusion, shock), but negative cultures [35]. A second obstacle is
technical and relates to the narrow spectrum of pathogens sought
in microbiology laboratories. For example, searching for Ureaplas-
ma and Mycoplasma spp. is not part of routine sepsis work-up in
neonates. A study that evaluated the frequency of umbilical CB
infections with these species found that that 23% of newborns born
,32 weeks tested positive for these pathogens [36]. Moreover, it is
plausible that analogous to AF infection, additional uncultivated
and difficult-to-cultivate species could be also etiological agents of
EONS [37].
Despite all the aforementioned obstacles, confirming or ruling-
out EONS has important clinical decision-making consequences
including prompt admission to NBSCU, antibiotic treatment, and
resource allocation [38]. Each hour of delayed treatment worsens
morbidity and mortality [39]. Forty-eight to 72 hours may pass
until bacterial growth can be confirmed. Because even a 4-hour
delay in initiation of antibiotics may increase neonatal mortality
related to sepsis, universal ‘‘empirical antibiotic therapy’’ is
advocated based on maternal risk factors and clinical suspicion
of EONS [40,41]. In most circumstances antibiotics are
discontinued, if microbial culture results are negative, and
neonatal clinical symptoms of sepsis absent [39–41]. In addition
to the considerable financial burden, [42] there are significant
downsides to this non-discriminatory therapeutic approach such as
frequent monitoring of antibiotic blood levels, renal and oto-
toxicity, increase risk of necrotizing enterocolitis (NEC) and
changing the diversity of microbes in NBSCUs [39,43,44]. As a
result, in the present state of clinical practice, hematological
indices are the only laboratory aids available to the neonatologist
with respect to clinical decisions to be made shortly after birth (i.e
admission to NBSCU, intravenous antibiotic treatment and
allocation of necessary resources) [13].
Attempts have been made to use physiologic parameters such as
cytokine profiles (i.e. IL-6, IL-1b, IL-8 and TNF-a), non-specific
acute-phase reactants (i.e. C-reactive protein, fibrinogen, amyloid
protein A, procalcitonin), neutrophil CD64 marker, or PCR to
identify neonates with EONS [45–48]. Unfortunately, clinical
evidence suggests that no currently available test or combination of
tests have sufficient sensitivity and specificity to ensure treatment
of infected newborns, while allowing non-treatment of the non-
infected infants. The time courses of many acute-phase reactants
suggest that the serum level of many of these cytokines increase 6
to 8 hours after the onset of illness and peak after 2 to 3 days [49].
Therefore, their clinical usefulness might be limited for a targeted
therapy immediately following birth. Hence, discovery of novel
biomarkers able of revealing pathogenic pathways disturbed in
fetuses exposed to infection while predicting the risk of EONS-
related complications is critical.
We found that antenatal exposure to IAI in newborns with
confirmed EONS affects major functional pathways including
transfer/carrier, immunity/defense, and protease/extracellular
matrix. Protein metabolism, blood circulation/gas exchange, lipid,
fatty acid and steroid metabolism are additionally disturbed
processes. Our proteomics discovery phase revealed alterations in
several proteins largely synthesized by hepatic parenchymal cells
(Hp, HpRP, AFP, VDBP, apopolipoproteins). Concerted changes
in their expression patterns are considered signatures of hepato-
cellular reaction and/or damage [50–53]. Therefore, the fetal liver
appears to be a key inflammatory target and an important control
point for homeostatic adjustments in the context of IAI.
There is evidence to suggest that AFP has multiple cell growth
regulating, differentiating and immunosuppressive activities
[54,55]. Besides serving as a transporter of vitamin-D, VDBP plays
an important role in response to tissue injury and a variety of
immune and inflammatory roles related to actin scavenging,
leukocyte chemotaxis and macrophage activation [56]. Down-
regulation of apolipoprotein’s expression may be partially respon-
sible for hyperlipidemia and increased triglyceride-rich lipoprotein
levels observed in septic neonates [57]. This phenomenon may have
Figure 9. Results of 2
nd-level validation against indicators of
adverse neonatal outcome and impact of expressed Hp
phenotype. (A) Forest plot illustrating the impact of newborn
classification on prediction of neonatal complications (2
nd-level
validation). Open circles indicate the log odds ratios based on each
newborn’s clinical diagnosis of EONS. Closed squares indicate the log
odds ratios based on assignment of newborns to either cluster-1 or
cluster-2 based on a probability level of .50%. The length of each line
shows the 95% confidence interval. The number of newborns affected
by each adverse outcome and levels of statistical significance are
included in Table 4. The asterisks (*) indicate major adverse outcomes
taken into account in the composite variable.
doi:10.1371/journal.pone.0026111.g009
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against LPS-induced inflammation and injury [58]. Besides their
down-regulation in inflammation, apolipoproteins may serve
functions other than regulating lipid metabolism, such as inhibition
of platelet aggregation and prostacyclin synthesis of the vascular
endothelium [59,60]. Recently, Ng et al. demonstrated that the
apolipoprotein metabolism is dysregulated in neonates with late-
onset sepsis and NEC [10]. Although the expression level of several
apolipoproteins (ApoA1, ApoA2, ApoC2, ApoC3) was decreased,
ApoC2 was the only non-redundant proteomic biomarker that
appeared to have diagnostic value for the aforementioned clinical
entities [10]. Developmental regulatory factors may impact on the
fetal versus neonatal biologic adaptive response to IAI and may
explain the differences the panel of dysregulated markers in cord
versus neonatal blood.
Candidate proteomic targets are traditionally validated on
alternative analytical platforms including ELISA. As shown, the
immunoassay levels of several of our initial candidate biomarkers
Table 4. Comparison of case classification by probability of ‘‘antenatal IAI exposure’’ with clinical diagnosis of EONS for prediction
of short-term adverse neonatal outcomes.
Adverse
outcomes
Newborns
with adverse
outcome/
total assessed
Classification by probability of
‘‘antenatal IAI exposure’’ (.50% Cluster-2) Classification by clinical diagnosis of EONS
YES 1 NO 1 P value OR [95% CI] NNH YES 1 NO 1 P value OR [95% CI] NNH
Individual outcomes
IVH 30/170 26 (30%) 4 (5%) ,0.001 8.7 [2.9-26.2] 2.3 15 (31%) 15 (12%) 0.007 3.2 [1.4-7.3] 3.8
IVH gr. 3-4 14/170 13 (15%) 1 (1%) 0.003 14.8 [1.9-115.8] 2.1 7 (15%) 7 (6%) 0.114 2.8 [0.9-8.5] 4.2
ROP 37/169 31 (36%) 6 (7%) ,0.001 7.2 [2.8-18.5] 2.4 16 (33%) 21 (17%) 0.040 2.4 [1.1-5.1] 5.3
ROP gr. 2-4 24/169 22 (26%) 2 (2%) ,0.001 13.9 [3.2-61.4] 2.1 11 (23%) 13 (11%) 0.072 2.5 [1.0-6.0] 4.9
NEC 27/170 19 (22%) 8 (9%) 0.027 2.9 [1.2-7.0] 4.0 12 (25%) 15 (11%) 0.042 2.6 [1.1-6.1] 4.8
NEC gr. 2-4 16/170 11 (12%) 5 (5%) 0.161 2.5 [0.8-7.5] 4.6 8 (17%) 8 (6%) 0.055 1.4 [0.4-4.9] 3.9
BPD 20/167 17 (22%) 3 (3%) ,0.001 8.2 [2.3-29.3] 2.3 11 (26%) 9 (45%) 0.003 4.6 [1.7-12] 2.9
Death 15/180 13 (15%) 2 (2%) 0.005 7.8 [1.7-35.7] 2.5 7 (15%) 8 (6%) 0.127 2.6 [0.9-7.7] 4.6
Composite outcomes
IVH or death 39/180 34 (39%) 5 (5%) ,0.001 11.0 [4.0-29.7] 2.0 18 (38%) 21 (16%) ,0.001 3.2 [1.5-6.7] 4.0
At least one
major adverse
outcome *
56/180 45 (51%) 11 (12%) ,0.001 7.7 [3.6-16.4] 2.2 26 (54%) 30 (23%) ,0.001 4.0 [2.0-8.1] 3.2
1Data presented as n (%) and analyzed by Chi square tests.
Includes newborns with at least one of the following outcomes: IVH grade 3–4, ROP grade 2–4, NEC grade 2–4, BPD and/or death.
*Abbreviations: EONS, early-onset neonatal sepsis; IVH, intraventricular hemorrhage; ROP, retinopathy of prematurity; NEC, necrotizing enterocolitis; BPD,
bronhopulmonary dysplasia; CI, confidence interval; OR, odds ratio; NNH, number needed to harm.
doi:10.1371/journal.pone.0026111.t004
Figure 10. Relationships among cluster assignment, cord blood haptoglobin (Hp) phenotype at birth and composite outcome
indicators. The percentages and the height of the grey or black portion of the bar indicate the proportion of newborns displaying the adverse
composite outcome ‘‘IVH or death’’ (A) or ‘‘at least one major adverse outcome’’ (B). Abbreviations: IVH, intraventricular hemorrhage; ROP,
retinopathy of prematurity; NEC, necrotizing enterocolitis; BPD, bronchopulmonary dysplasia; EONS, early-onset neonatal sepsis; IAI, intra-amniotic
infection and/or inflammation.
doi:10.1371/journal.pone.0026111.g010
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implies that several proteomic targets may not be clinically useful
biomarkers when assessed through available immunoassays,
involvement of the represented pathways in the pathophysiology
of EONS should not be discredited. The apparent discrepancy is
easily reconciled by technical aspects of both methods. ELISAs
measure immunoreactivity of generic proteins, which, in EONS
may undergo proteolysis. 2D-DIGE identifies the resulting
fragments as distinct up- or down-regulated spots depending on
the degree and sites of proteolysis. Yet, immunoreactive levels may
not be impacted in parallel, as these largely depend on whether the
proteolytic process affects the epitopes. In contrast to proteomics
techniques, immunoassays evaluate proteins in native conditions
with tertiary and quaternary structures independently impacting
optical density [61]. In many instances, ELISAs do not
discriminate among closely related proteins or among subunits
of the same protein [61]. Our finding that the Hp&HpRP ELISA
level sums the immunoreactivity of closely related proteins
supports the complexity of this problem.
Hp is an acute-phase reactant glycoprotein primarily of
hepatocytic origin [30]. Biological functions of Hp with potential
roles in protecting the fetus and neonate from inflammation-
derived injury include: scavenging of toxic hemoglobin, [62]
dampening of neutrophilic oxidative burst, [63] inhibition of
endotoxin-induced inflammation, suppression of monocytic TNF-
a and IL-12 production, [64] and inhibition of B and T
lymphocyte proliferation [65] IL-6 is a known transcriptional
activator of Hp [66] and may explain why histological chorioam-
nionitis was associated with increased CB Hp levels [67]. It is
believed that a gene located 2.2kb downstream to human Hp locus
codes HpRP, [30] which in adult serum accounts for only ,7% of
total Hp&HpRP [68]. The a- and b-chains of HpRP are distinct,
yet highly (,90%) homologous with those of Hp, making
separation of the two proteins difficult. A distinct role for HpRP
in innate immunity was proposed recently in defense against
trypanosome infection [69].
Our proteomic data complemented by ELISA and Western
blotting provides methodologically unbiased evidence that expo-
sure of the fetus to IAI leads to a precocious switch-on in Hp
expression. These results resolve conflicting aspects in the
literature regarding Hp. Following its description in 1938, [70]
Hp was considered near-absent at birth switching to adult levels
within the first year of life [71,72]. We confirmed near-absent Hp
in healthy term newborns. However, a few earlier studies reported
assayable Hp in CB or neonatal blood, yet specifically noted that
Hp level was not useful as marker of newborn sepsis [73–75]. The
mix of term with preterm subjects, of early- and late-onset sepsis,
inability to concurrently assess for IAI, reliance on less sensitive
laboratory techniques optimal for assessing adult and nor cord
blood Hp levels and on conventional statistics explain the
discrepant conclusions among these reports, while supporting the
novelty of our approach and findings.
The performance of a new diagnostic test is traditionally
evaluated relative to a perfect ‘‘gold standard’’. The current gold
standard for infection, namely blood cultures, has well recognized
limitations [76]. Clinical circumstances surrounding delivery (i.e.
antenatal antibiotics, uncultivable bacteria as etiological agents,
specimen contamination ex-vivo) increase the odds for EONS
misclassification [37]. Our approach of using LCA was aimed to
circumvent this obstacle [33,77]. We established a diagnostic
algorithm that adds two CB biochemical markers, (Hp&HpRP
switch pattern and IL-6) to the hematological indices used for
presumed EONS. When compared to clinical protocols for
ascertaining EONS, our algorithm improved the predictive odds
for postnatal complications, such as IVH which is known to have
antenatal antecendants related to IAI [78]. Yet, Hp&HpRP
switching exerted the highest discriminative power. When
switched-on at birth, this biomarker alone resulted in probability
of IAI of .70%.
An important regulator of Hp expression is the inflammatory
cytokine IL-6 [66]. Hepatic Hp synthesis is dependent on cis-
acting elements localized within the first 186 bp of the 59-flanking
region of the promoter [66]. Interaction of this promoter site with
trans-acting elements is postulated to provide a 2-nd level of
complexity in regulation of Hp expression. These observations
may explain why individuals with the same Hp genotype, the
levels of Hp vary with exposure to environmental or epigenetic
stressors (physical effort, methylation status) [79]. Few individuals
may lack both Hp alleles giving raise to Hp0-0 phenotype. In the
US adult population, ahaptoglobinemia varies from 0.1% in
Caucasians to much higher frequency 4% in African-Americans.
Studies in knock-out mice have demonstrated that ahaptoglobi-
nemia is associated with higher malarial parasitic burden
consistent with Hp’s beneficial role in protecting against infection
[80].
In our study, the addition of CB IL-6 to the Hp switch pattern
was useful only to solve as as ‘‘likely exposed’’ a minority of cases
(,3%, 5/180) that paradoxically retained the Hp switch-off
pattern despite elevated CB IL-6 levels (range 110–1,533 pg/mL).
One of these cases had confirmed EONS. Following our validation
phase and LCA analysis, it became apparent that these cases
represented ahaptoglobinemic outliers. We found that newborns
retaining the Hp0-0 phenotype despite antenatal IAI exposure had
an increased frequency of adverse outcomes consistent with the
important anti-inflammatory and anti-microbial roles of Hp [64].
Thus, functional hypo- or ahaptoglobinemia may increase
susceptibility to infection, inflammation and cell damage.
Although in our study, the number of newborns with this
phenotype (high CB IL-6 and switch-off Hp pattern) was likely
too small for LCA to identify a third cluster, our algorithm permits
isolation of this subgroup of newborns for future genetic and
promoter kinetics studies.
The predictive value of Hp&HpRP switching as biomarker of
antenatal IAI exposure was independent of GA and of its absolute
concentration, which was phenotype-dependent. The disparity in
Hp phenotypes among individuals has been studied extensively in
relationship to susceptibility to infection as well as chronic diseases
with oxidative component [81]. It has been suggested that
individuals of Hp1-1 phenotype are able to handle free
hemoglobin more efficiently but also to have reduced antibody
responses due to the greater ability of Hp1-1 to inhibit lymphocyte
transformation. In contrast, Hp2-2 individuals tend to have higher
antibody responses and relative protection against infection at the
expense of higher incidence of autoimmune conditions. Macro-
phages activated by the polymeric Hp2-2, shift the T-helper cell
response toward Th-1 cytokines (IL-2, interferon-c, lymphotoxins),
while those activated by Hp1-1 synthesize more Th-2 cytokines
(IL-4, IL-5, IL-6, IL-10) [82]. Our finding that Hp2-2 newborns
appear to have better outcomes independent of prematurity is
provocative and concurs with the idea that the Hp2 allele may
offer survival advantage for this population.
In summary, we carried out a proteomics study to identify CB
biomarkers of EONS and found that a switch-on in Hp&HpRP
expression reflected a fetal adaptive response to IAI exposure in
utero. Assessment of CB Hp&HpRP switch pattern carries the
potential for quick turn-around and may provide useful informa-
tion for neonatal risk stratification even in the absence of
amniocentesis or placental histology. We propose that this
Cord Blood Biomarkers and Neonatal Sepsis
PLoS ONE | www.plosone.org 13 October 2011 | Volume 6 | Issue 10 | e26111biomarker could be a useful addition to the diagnostic work-up of
EONS to increase the level of confidence that the newborn is at
high risk of prematurity-related complications.
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